$RPRX News

Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Royalty Pharma (NASDAQ:RPRX) Hits Perfect Technical Rating with Breakout Setup

Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript

JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Royalty Pharma (NASDAQ:RPRX) Beats Q2 Revenue Estimates, Raises Full-Year Guidance

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma reports second quarter 2026 results

Royalty Pharma plc 2026 Q2 - Results - Earnings Call Presentation

Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Royalty Pharma: At The Right P/E, I'm In (But Not Here)

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

Royalty Pharma (RPRX) Could Be 40% Undervalued After Its Dividend Decision